Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%)

Main Article Content

Bruce Strober
Manish Patel
Mark I Kaldas
Greg St John
Vishvas Garg
Adam P Sima
Thomas Eckmann
Alicia Beeghly
April Armstrong

Keywords

IL-23 inhibitor, Psoriasis, Risankizumab, high-impact area, skin clearance, quality of life

Abstract

none

References

1. Strober, B, et al. J Am Acad Dermatol. 2020;82(1):117–22.

2. Strober, et al. J Dermatolog Treat. 2024;Dec;35(1):2287401.

3. SKYRIZI Prescribing Information. AbbVie Inc., North Chicago, IL. 01/2022.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>